Where Does Teva Pharmaceutical Industries Limited (TEVA) Rank When It Comes To Price-To-Earnings Ratio?


Teva Pharmaceutical Industries Limited (NYSE:TEVA) finished Thursday with a subtraction of -$0.16 to close at $8.06, a downside of -1.95 percent. An average of 9,221,440 shares of common stock have been traded in the last five days. There was a fall of -$0.83 in the past week, and it reached a new high 15 times over the past 12 months. The last 20 days have seen an average of 9,559,750 shares traded, while the 50-day average volume stands at 14,317,061.

TEVA stock has decreased by -19.88% in the last month. The company shares reached their 1-month lowest point of $8.00 on 09/22/22. With the stock rallying to its 52-week high on 08/11/22, shares of the company touched a low of $6.78 and a high of $11.34 in 52 weeks. It has reached a new high 19 times so far this year and achieved 0.62% or $0.05 in price. In spite of this, the price is down -28.92% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Insider Transactions

32 days have passed since Teva Pharmaceutical Industries Limited (TEVA) last reported insider trading activity. Kalif Eliyahu Sharon, who is EVP, Chief Financial Officer, most recently acquired $55,500 shares at $10.07 per share on Aug 22. In this transaction, the insider spent $558,696. Exec. VP Chief Legal Officer, Stark David Matthew, disposed of 58,163 shares at a price of $9.04 on Jul 28. The insider now owns more than $525,590 worth of shares. Prior to that, Executive VP, Global R&D Fridriksdottir Hafrun went on to Sale 130,000 shares at $8.22 each on May 17. An amount of $1,068,067 was transacted.

Valuation Metrics

Teva Pharmaceutical Industries Limited (TEVA) stock’s beta is 1.26. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.59, the price-to-book (PB) ratio at 0.99, and the price-to-cash flow ratio at 19.25.

Financial Health

The quick ratio of Teva Pharmaceutical Industries Limited for the three months ended June 29 was 0.70, and the current ratio was 1.10, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.25 and a total debt to equity ratio of 2.44 for the quarter ending June 29. Teva Pharmaceutical Industries Limited’s EBITDA margin for the year ending June 29 is 27.75%, while its operating margin for the same period stands at -6.20%. Its gross profit as reported stood at $7.59 billion compared to revenue of $15.88 billion.

Earnings Surprise

For the three-month period that ended June 29, Teva Pharmaceutical Industries Limited had $20.36 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$232.0 million in the quarter, while revenues were grew 189.22%. The analyst consensus anticipated Teva Pharmaceutical Industries Limited’s latest quarter earnings to come in at $0.56 per share, but it turned out to be $0.68, a 21.40% surprise. For the quarter, EBITDA amounted to -$592.0 million. Shareholders own equity worth $1.11 billion.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Teva Pharmaceutical Industries Limited (TEVA) price momentum. RSI 9-day as of the close on 22 September was 19.97%, suggesting the stock is oversold, with historical volatility in this time frame at 27.81%.

As of today, TEVA’s price is $8.44 -9.34% or -$0.83 from its 5-day moving average. TEVA is currently trading -19.64% lower than its 20-day SMA and -7.46% lower than its 100-day SMA. However, the stock’s current price level is +15.97% above the SMA50 and -2.18% below the SMA200.

The stochastic %K and %D were 9.11% and 18.38%, respectively, and the average true range (ATR) was 0.30. With the 14-day stochastic at 4.23% and the average true range at 0.32, the RSI (14) stands at 28.96%. The stock has reached -0.48 on the 9-day MACD Oscillator while the 14-day reading was at -0.55.

Analyst Ratings

BofA Securities upgraded Teva Pharmaceutical Industries Limited (NYSE: TEVA) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Teva Pharmaceutical Industries Limited (TEVA) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell TEVA, while 11 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 1 others rate it as a “buy”.

What is TEVA’s price target for the next 12 months?

Analysts predict a range of price targets between $8.00 and $13.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Teva Pharmaceutical Industries Limited (TEVA) stock is $10.56.


Please enter your comment!
Please enter your name here